EUVIMEDEUVIMED entdecken
Crossref

4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations

MORGAN BRINSON, FADI SHEHADEH, ASHUTOSH SABHARWAL, ABHISHEK KANSARA

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-4-pub ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von MORGAN BRINSON und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Cardiovascular (CV) disease is the leading cause of death in individuals over age 45 and adults with type 2 diabetes (T2D) have 2-4 times higher risk of CV morbidity and mortality. While the economic burden of CV disease is expected to increase by 2050, CV outcome trials highlighting beneficial effects of GLP-1RA and SGLT2i have failed to sufficiently include diverse race/ethnic patient populations. Hence, these benefits are yet to be quantified across populations. With this study, we aim to understand the major adverse CV events (MACE) across diverse populations using these pharmacotherapeutic agents.

Methods

We retrospectively analyzed 11,300 individuals with T2D on antihyperglycemic medications and assessed MACE outcomes. MACE was defined using CV death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure, and ischemia-driven revascularization. Logistic regression assessed MACE occurrence post-antihyperglycemic initiation, factoring in age, sex, race/ethnicity, type of antihyperglycemic (GLP-1RA, SGLT2i, or other), and associated comorbidities.

Results

Non-Hispanic White (NHW) population using GLP-1RAs experienced a 31.5% reduction in MACE outcomes compared to those on other antihyperglycemic medications. While Hispanic White (HW) and NHB populations demonstrated a 42.5% and 23.7% reduction, respectively, the Asian (A) population did not notice statistically significant benefits in MACE outcomes. Furthermore, SGLT2i revealed no notable reduction in MACE across all race/ethnicities.

Conclusion

GLP-1RA effectively reduced MACE risk among HW and NHB but not in the A population. Also, SGLT2i demonstrated no significant benefits. These results underscore the importance of tailored diabetes treatment and the need for further exploration into contributing disparities. Disclosure M. Brinson: None. F. Shehadeh: None. A. Sabharwal: None. A. Kansara: Research Support; Current; Eli Lilly and Company. Research Support; Ended; Medtronic. Research Support; Current; Arrowhead Pharmaceuticals, Calcilytix, Inc. Research Support; Ended; Amolyt. Research Support; Current; Endogenex. Advisory Panel; Ended; Veracyte, Crinetics Pharmaceuticals, Inc. Funding Digital Health Workshop Seed Award

Zitieren

APA

BRINSON, M., SHEHADEH, F., SABHARWAL, A., & KANSARA, A. (2026). 4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-4-pub

Vancouver

BRINSON M, SHEHADEH F, SABHARWAL A, KANSARA A. 4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-4-pub

BibTeX
@article{BRINSON2026,
  author = {BRINSON, MORGAN and SHEHADEH, FADI and SABHARWAL, ASHUTOSH and KANSARA, ABHISHEK},
  title = {4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-4-pub}
}
Kostenlos starten →